Physician profile
Ben W Seale
NPI 1720129950
$622,863.61
in general payments reported to CMS, 2019-2025
63 companies · $66K in 2025
The $66K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $109K · 2021: $85K · 2022: $128K · 2023: $59K · 2024: $64K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Food and Beverage: $12K · Travel and Lodging: $8,038 · Education: $59.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,391.00 |
| Food and Beverage | $11,848.91 |
| Travel and Lodging | $8,038.21 |
| Education | $59.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $336,967.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $177,195.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $38,411.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $20,420.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $17,914.98 | 2019-2020 | |
| Abbvie INC. | $17,321.82 | 2019-2025 | Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,512.64 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $1,283.59 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $1,250.41 | 2019-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Corcept Therapeutics | $1,191.62 | 2019-2025 | Korlym |
| Dexcom, INC. | $993.01 | 2021-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $974.75 | 2024-2025 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $969.94 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $799.12 | 2022-2025 | |
| Insulet Corporation | $693.07 | 2019-2025 | Omnipod |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $561.28 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Recordati_rare_diseases_inc. | $422.33 | 2020-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $311.36 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.53 | 2019-2022 | |
| Esperion Therapeutics, INC. | $267.33 | 2020-2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $256.74 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $183.51 | 2020-2024 | Unithroid |
| Lifescan, INC. | $183.08 | 2019-2022 | |
| Pfizer INC. | $165.99 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $165.31 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $151.01 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Becton, Dickinson and Company | $125.56 | 2020-2022 | |
| Eisai INC. | $124.08 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $115.53 | 2024-2025 | |
| Ibsa Pharma INC. | $113.41 | 2020-2023 | Tirosint, Licart |
| Grt US Holding, INC. | $107.71 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $106.62 | 2022-2025 | Yorvipath |
| Chiesi USA, INC. | $95.27 | 2024-2025 | Mycapssa |
| Antares Pharma, INC. | $85.85 | 2024-2025 | Xyosted |
| Horizon Therapeutics Plc | $83.26 | 2022-2023 | Tepezza |
| Sequel Med Tech, LLC | $77.52 | 2025 | Twiist |
| Kyowa Kirin, INC. | $77.28 | 2023-2024 | Crysvita |
| Amryt Pharma Holdings Ltd | $75.63 | 2023 | Mycapssa |
| Cequr Corporation | $74.21 | 2024-2025 | Cequr Simplicity |
| Eusa Pharma (US) LLC | $66.78 | 2022 | |
| Stryker Corporation | $58.51 | 2024 | T2 Alpha |
| Embecta Corp. | $56.70 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Janssen Scientific Affairs, LLC | $55.46 | 2019 | |
| Astellas Pharma US INC | $53.48 | 2023-2025 | Veozah |
| Amarin Pharma, INC. | $47.66 | 2019 | |
| Zealand Pharma US, INC. | $40.42 | 2020-2021 | |
| Shire North American Group INC | $39.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $36.31 | 2021 | |
| Tolmar, INC. | $29.77 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.81 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $28.24 | 2024 | Strensiq |
| Medtronic Minimed, INC. | $26.53 | 2020 | |
| Rochester Medical Corporation | $19.66 | 2021 | |
| Alfasigma USA, INC. | $19.62 | 2020 | |
| Halozyme INC | $18.96 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $18.78 | 2020 | |
| Aegerion Pharmaceuticals, INC. | $17.05 | 2019 | |
| Acella Pharmaceuticals, LLC | $16.26 | 2024 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $15.35 | 2023 | Nexlizet, Contrave, Nexletol |
| Regeneron Healthcare Solutions, INC. | $15.06 | 2019 | |
| Ascensia Diabetes Care US INC. | $14.44 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $11.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Seale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.